These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 11166518

  • 21. Growth hormone and prolactin response to apomorphine in bipolar and unipolar depression.
    McPherson H, Walsh A, Silverstone T.
    J Affect Disord; 2003 Sep; 76(1-3):121-5. PubMed ID: 12943941
    [Abstract] [Full Text] [Related]

  • 22. Neuroendocrine findings in the schizophrenias.
    Garver DL.
    Endocrinol Metab Clin North Am; 1988 Mar; 17(1):103-9. PubMed ID: 2897906
    [Abstract] [Full Text] [Related]

  • 23. Growth hormone response to apomorphine in obsessive-compulsive disorder.
    Pitchot W, Hansenne M, Moreno AG, Ansseau M.
    J Psychiatry Neurosci; 1996 Nov; 21(5):343-5. PubMed ID: 8973055
    [Abstract] [Full Text] [Related]

  • 24. Prolactin and growth hormone responses to growth hormone-releasing hormone in acute schizophrenia.
    Nerozzi D, Magnani A, Sforza V, Scaramucci E, Cerilli M, Moretti C, Antonozzi I, Frajese G.
    Neuropsychobiology; 1990 Nov; 23(1):15-7. PubMed ID: 2280826
    [Abstract] [Full Text] [Related]

  • 25. Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics.
    Zhang XY, Zhou DF, Cao LY, Wu GY, Shen YC.
    Neuropsychopharmacology; 2005 Aug; 30(8):1532-8. PubMed ID: 15886721
    [Abstract] [Full Text] [Related]

  • 26. Growth hormone responses to graded doses of apomorphine HCl in schizophrenia.
    Cleghorn JM, Brown GM, Brown PJ, Kaplan RD, Mitton J.
    Biol Psychiatry; 1983 Aug; 18(8):875-85. PubMed ID: 6137249
    [Abstract] [Full Text] [Related]

  • 27. Effects of apomorphine on blood levels of homovanillic acid, growth hormone and prolactin in medicated schizophrenics and healthy control subjects.
    Scheinin M, Syvälahti EK, Hietala J, Huupponen R, Pihlajamäki K, Seppälä OP, Säkö E.
    Prog Neuropsychopharmacol Biol Psychiatry; 1985 Aug; 9(4):441-9. PubMed ID: 2866563
    [Abstract] [Full Text] [Related]

  • 28. A psychoncological study of lymphocyte subpopulations in relation to pleasure-related neurobiochemistry and sexual and spiritual profile to Rorschach's test in early or advanced cancer patients.
    Messina G, Lissoni P, Bartolacelli E, Tancini G, Villa S, Gardani GS, Brivio F.
    J Biol Regul Homeost Agents; 2003 Aug; 17(4):322-6. PubMed ID: 15065761
    [Abstract] [Full Text] [Related]

  • 29. Apomorphine-induced growth hormone response is attenuated by ethanol but not dextromethorphan.
    Budde H, Zimmermann US, Steffin B, Rommelspacher H, Schmidt LG, Smolka MN.
    Alcohol Clin Exp Res; 2007 Jan; 31(1):100-3. PubMed ID: 17207107
    [Abstract] [Full Text] [Related]

  • 30. Nocturnal hormone profiles in patients with schizophrenia treated with olanzapine.
    Mann K, Rossbach W, Müller MJ, Müller-Siecheneder F, Pott T, Linde I, Dittmann RW, Hiemke C.
    Psychoneuroendocrinology; 2006 Feb; 31(2):256-64. PubMed ID: 16185814
    [Abstract] [Full Text] [Related]

  • 31. [The biological basis of suicidal behavior: neuroendocrine and psychophysiological approach to the role of catecholamines].
    Pitchot W, Hansenne M, Gonzalez Moreno A, Wauthy J, Ansseau M.
    Acta Psychiatr Belg; 1995 Feb; 95(4-5):210-33. PubMed ID: 8525861
    [Abstract] [Full Text] [Related]

  • 32. Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease.
    Happe S, Tings T, Helmschmied K, Neubert K, Wuttke W, Paulus W, Trenkwalder C.
    Mov Disord; 2004 Dec; 19(12):1511-5. PubMed ID: 15390061
    [Abstract] [Full Text] [Related]

  • 33. Schneider's first-rank symptoms of schizophrenia. An association with increased growth hormone response to apomorphine.
    Whalley LJ, Christie JE, Brown S, Arbuthnott GW.
    Arch Gen Psychiatry; 1984 Nov; 41(11):1040-3. PubMed ID: 6497565
    [Abstract] [Full Text] [Related]

  • 34. Neuroendocrine measures of dopaminergic function in chronic cocaine users.
    Lee MA, Bowers MM, Nash JF, Meltzer HY.
    Psychiatry Res; 1990 Aug; 33(2):151-9. PubMed ID: 2243892
    [Abstract] [Full Text] [Related]

  • 35. Injection of apomorphine--a test to predict individual different dopaminergic sensitivity?
    Surmann A, Havemann-Reinecke U.
    J Neural Transm Suppl; 1995 Aug; 45():143-55. PubMed ID: 8748620
    [Abstract] [Full Text] [Related]

  • 36. Neuroendocrine effects of apomorphine in chronic schizophrenic patients under long-term neuroleptic therapy and after drug withdrawal: relations to psychopathology and tardive dyskinesia.
    Müller-Spahn F, Ackenheil M, Albus M, May G, Naber D, Welter D, Zander K.
    Psychopharmacology (Berl); 1984 Aug; 84(3):436-40. PubMed ID: 6151210
    [Abstract] [Full Text] [Related]

  • 37. Dopamine receptor alteration in schizophrenia: neuroendocrine evidence.
    Rotrosen J, Angrist BM, Gershon S, Sachar EJ, Halpern FS.
    Psychopharmacology (Berl); 1976 Dec 21; 51(1):1-7. PubMed ID: 827770
    [Abstract] [Full Text] [Related]

  • 38. The two-syndrome concept and neuroendocrinology of schizophrenia.
    Crow TJ, Ferrier IN, Johnstone EC.
    Psychiatr Clin North Am; 1986 Mar 21; 9(1):99-113. PubMed ID: 2870481
    [Abstract] [Full Text] [Related]

  • 39. Effects of apomorphine and haloperidol on plasma cortisol levels in conscious dogs.
    Uvnäs-Wallensten K, Goiny M, Oriowo MA, Cekan S.
    Acta Physiol Scand; 1981 Jul 21; 112(3):253-6. PubMed ID: 7293796
    [Abstract] [Full Text] [Related]

  • 40. Neuroendocrine effects of apomorphine: characterization of response patterns and application to schizophrenia research.
    Rotrosen J, Angrist B, Gershon S, Paquin J, Branchey L, Oleshansky M, Halpern F, Sachar EJ.
    Br J Psychiatry; 1979 Nov 21; 135():444-56. PubMed ID: 540209
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.